Loading...
Cost-Benefit Analysis of a Chlamydia trachomatis Vaccine Program in Adolescent Girls in the United States.
Journal Title
Journal of the Pediatric Infectious Diseases Society
Keywords
Readers/Advisors
Journal Title
Term and Year
Publication Date
2018-12-03
Book Title
Publication Volume
7
Publication Issue
4
Publication Begin
296
Publication End
302
Number of pages
Collections
Files
Loading...
pix072.pdf
Adobe PDF, 275.71 KB
Research Projects
Organizational Units
Journal Issue
Abstract
With >1.4 million cases in the United States reported to the Centers for Disease Control and Prevention in 2012, Chlamydia trachomatis infection is a major public health concern. We examined the impact of a C trachomatis vaccination program using a decision-analysis model to estimate the effects of vaccination on C trachomatis-associated costs and morbidity.
We developed a Markov model considering a cohort of 2158117 US females aged 9 to 26 years. Morbidity, death, and healthcare-associated costs associated with chlamydial infection of mothers and fetuses/neonates were calculated over a 17-year time frame. We developed 2 major comparison arms, namely, a C trachomatis vaccination program and no C trachomatis vaccination program. Base-case efficacy and coverage were set to those of human papillomavirus in the United States with all variables, including efficacy and coverage, ranged in sensitivity analyses.
On the basis of a base-case analysis, a vaccination program would cost an estimated $710 million for a cohort of 2158117 women over a 17-year period, an increase of $41 million over having no vaccination program. A vaccination program would prevent 34000 cases of C trachomatis infection and 5976 cases of pelvic inflammatory disease.
A C trachomatis vaccination program results in increased cost to the healthcare system but averts significant morbidity and death.
We developed a Markov model considering a cohort of 2158117 US females aged 9 to 26 years. Morbidity, death, and healthcare-associated costs associated with chlamydial infection of mothers and fetuses/neonates were calculated over a 17-year time frame. We developed 2 major comparison arms, namely, a C trachomatis vaccination program and no C trachomatis vaccination program. Base-case efficacy and coverage were set to those of human papillomavirus in the United States with all variables, including efficacy and coverage, ranged in sensitivity analyses.
On the basis of a base-case analysis, a vaccination program would cost an estimated $710 million for a cohort of 2158117 women over a 17-year period, an increase of $41 million over having no vaccination program. A vaccination program would prevent 34000 cases of C trachomatis infection and 5976 cases of pelvic inflammatory disease.
A C trachomatis vaccination program results in increased cost to the healthcare system but averts significant morbidity and death.
Citation
Ditkowsky J, Rahman A, Hammerschlag MR, Kohlhoff S, Smith-Norowitz TA. Cost-Benefit Analysis of a Chlamydia trachomatis Vaccine Program in Adolescent Girls in the United States. J Pediatric Infect Dis Soc. 2018 Dec 3;7(4):296-302. doi: 10.1093/jpids/pix072. PMID: 28992068.